About
Vascular
Therapies

Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery.

Sirogen™ is currently undergoing the ACCESS 2 clinical trial to determine its safety and effectiveness in improving vascular access outcomes in patients 65 years and older requiring an arteriovenous fistula for hemodialysis.

Management

our Team has extensive experience developing and commercializing new drugs and medical devices

Headshot of CEO John McDermott

John

McDermott

Chief Executive Officer
Headshot of CEO John McDermott

Sriram Iyer,

MD, FACC, FSCAI

Chief Scientific Officer
Headshot of CEO John McDermott

Rosanne

Terraciano

Vice President of Operations
Headshot of CEO John McDermott

Paul Barkofsky,

PhD

Vice President of New Product Development
Headshot of CEO John McDermott

Rakesh

Raghubanshi

Vice President of Clinical Affairs
Headshot of CEO John McDermott

Maureen

Harrison

Vice President of Quality Assurance
Headshot of CEO John McDermott

Ronald E.

Eggan, Jr.

Senior Director of Manufacturing

Board of Directors

Vascular Therapies' Board of Directors is comprised of experts from the fields of medicine, medical technology, finance, and life science investing.

Robert Croce CHAIRMAN
John McDermott CEO
Gerald Dorros, M.D.
Robert Flanagan
Sriram Iyer, MD, FACC, FSCAI CHIEF SCIENTIFIC OFFICER / FOUNDER
Andrew Midler
Daniel M. Ryan

Contact

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

CAUTION: THE SIROLIMUS-ELUTING COLLAGEN IMPLANT (SIROGENTM) IS AN INVESTIGATIONAL PRODUCT THAT IS NOT AVAILABLE FOR SALE IN ANY COUNTRY. READ OUR Expanded Access Policy.